NCT01456676View on ClinicalTrials.gov

Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Interventions
DRUG

Nilotinib + LDE225

Nilotinib is an aminopyrimidine ATP-competitive inhibitor of the protein tyrosine kinaseactivity of BCR-ABL.

Trial Locations (7)

13273

Novartis Investigative Site, Marseille

28006

Novartis Investigative Site, Madrid

31008

Novartis Investigative Site, Pamplona

60590

Novartis Investigative Site, Frankfurt

89081

Novartis Investigative Site, Ulm

M5G 2M9

Novartis Investigative Site, Toronto

00161

Novartis Investigative Site, Roma

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY